2012
Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-Term Survivors of Gastric Cancer: A California Population-Based Study. Journal Of Clinical Oncology 2012, 30: 3507-3515. PMID: 22949151, DOI: 10.1200/jco.2011.35.8028.Peer-Reviewed Original ResearchConceptsDisease-specific survivalMedian disease-specific survivalGEJ cancerGastric cancerIntestinal histologyAsian/Pacific Islander raceNational Cancer Institute's SurveillanceCox proportional hazards modelEsophagus/cardiaCalifornia Cancer RegistryPacific Islander raceGastroesophageal junction adenocarcinomaKaplan-Meier curvesEnd Results ProgramCases of gastricSocioeconomic status quintileProportional hazards modelJunction adenocarcinomaPathologic characteristicsTerm survivorsCancer RegistryTumor characteristicsDiffuse histologyHispanic raceResults ProgramHER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry & Molecular Morphology 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/pai.0b013e31821c821c.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBreast NeoplasmsEsophageal NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMaleMiddle AgedReceptor, ErbB-2Retrospective StudiesStomach NeoplasmsUnited StatesConceptsGastroesophageal junction cancerHER2-positive adenocarcinomaGastroesophageal junction carcinomaJunction cancerHER2 expressionHER2 statusClinical Oncology/CollegeHER2-positive gastricGastroesophageal junction adenocarcinomaGastric Cancer TrialIntestinal-type adenocarcinomaPrimary tumor siteMembranous staining patternHER2/CEP17 ratioPrimary gastric adenocarcinomaTissue microarray approachASCO/CAPHER2 gene amplificationHER2 protein expressionJunction adenocarcinomaDiffuse adenocarcinomaGastroesophageal junctionPatient survivalTherapeutic optionsIntestinal type
2009
Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Kunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.Peer-Reviewed Original ResearchStanford Cancer CenterGastroesophageal junction cancerMetastatic gastricJunction cancerRetrospective reviewPossible treatment-related deathSingle-institution retrospective reviewCarboplatin AUC 6Regimen of carboplatinCycles of chemotherapyMedian overall survivalTreatment-related deathsStandard chemotherapy regimenFourty-five patientsGastroesophageal junction adenocarcinomaFluoropyrimidine-based treatmentSignet ring featuresAUC 6Chemotherapy-naïvePo bidChemotherapy regimenOnly patientsOverall survivalJunction adenocarcinomaMedian age